These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 31346782)

  • 1. Commentary/Introduction for "Debate on Insulin vs. Non-insulin Use in the Hospital Setting" Articles.
    Wallia A; Seley JJ
    Curr Diab Rep; 2019 Jul; 19(9):63. PubMed ID: 31346782
    [No Abstract]   [Full Text] [Related]  

  • 2. Molecular mechanisms by which GLP-1 RA and DPP-4i induce insulin sensitivity.
    Yaribeygi H; Sathyapalan T; Sahebkar A
    Life Sci; 2019 Oct; 234():116776. PubMed ID: 31425698
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Not Available].
    Toft E; Rydén M
    Lakartidningen; 2018 Feb; 115():. PubMed ID: 29461566
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Infectious complications of newer agents in the fight against diabetes.
    Stover KR; Hugh E; Sherman JJ; Malinowski SS; Berdahl GJ; Riche DM
    Nurse Pract; 2020 Nov; 45(11):17-24. PubMed ID: 33093391
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incretin-based medications (GLP-1 receptor agonists, DPP-4 inhibitors) as a means to avoid hypoglycaemic episodes.
    Farngren J; Ahrén B
    Metabolism; 2019 Oct; 99():25-31. PubMed ID: 31279738
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Positioning SGLT2 Inhibitors/Incretin-Based Therapies in the Treatment Algorithm.
    Wilding JP; Rajeev SP; DeFronzo RA
    Diabetes Care; 2016 Aug; 39 Suppl 2():S154-64. PubMed ID: 27440828
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glucose lowering and the kidney: are all drug classes equal?
    Wong MG; Jardine M; Perkovic V
    Lancet Diabetes Endocrinol; 2018 Nov; 6(11):835-837. PubMed ID: 30292590
    [No Abstract]   [Full Text] [Related]  

  • 8. Combination therapy with DPP-4 inhibitors and insulin in patients with type 2 diabetes mellitus: what is the evidence?
    Charbonnel B; Schweizer A; Dejager S
    Hosp Pract (1995); 2013 Apr; 41(2):93-107. PubMed ID: 23680741
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanistic insights from sequential combination therapy with a sodium glucose co-transporter-2 inhibitor and a dipeptidyl peptidase-4 inhibitor: Results from the CANARIS Trial using canagliflozin and teneligliptin.
    Okahata S; Sakamoto K; Mitsumatsu T; Kondo Y; Tanaka S; Shiba T
    Diabetes Obes Metab; 2019 Feb; 21(2):388-392. PubMed ID: 30146790
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New Glucose-Lowering Agents for Diabetic Kidney Disease.
    de Vos LC; Hettige TS; Cooper ME
    Adv Chronic Kidney Dis; 2018 Mar; 25(2):149-157. PubMed ID: 29580579
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Programs for continuing medical education: a session; 7. Recent trends in treatment of diabetes mellitus].
    Namba M
    Nihon Naika Gakkai Zasshi; 2014 Mar; 103(3):657-64. PubMed ID: 24796133
    [No Abstract]   [Full Text] [Related]  

  • 12. SGLT2 Inhibitors in Combination Therapy: From Mechanisms to Clinical Considerations in Type 2 Diabetes Management.
    van Baar MJB; van Ruiten CC; Muskiet MHA; van Bloemendaal L; IJzerman RG; van Raalte DH
    Diabetes Care; 2018 Aug; 41(8):1543-1556. PubMed ID: 30030256
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dipeptidyl peptidase-4 inhibitors in triple oral therapy regimens in patients with type 2 diabetes mellitus.
    Barnett AH; Charbonnel B; Moses RG; Kalra S
    Curr Med Res Opin; 2015; 31(10):1919-31. PubMed ID: 26361231
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Insulin pump therapy guidelines for China (July 2010).
    Mu Y; Yin S;
    J Diabetes; 2012 Jun; 4(2):127-39. PubMed ID: 22107806
    [No Abstract]   [Full Text] [Related]  

  • 15. [Treatment strategy for elderly diabetic patient with insulin or GLP-1 receptor agonist].
    Ando Y
    Nihon Rinsho; 2013 Nov; 71(11):1993-8. PubMed ID: 24397172
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Attention to the use of oral anti-diabetic medication in older adults with type 2 diabetes].
    Jojima T; Aso Y
    Nihon Rinsho; 2013 Nov; 71(11):1987-92. PubMed ID: 24397171
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Teneligliptin improves glycemic control with the reduction of postprandial insulin requirement in Japanese diabetic patients.
    Tsuchimochi W; Ueno H; Yamashita E; Tsubouchi C; Sakoda H; Nakamura S; Nakazato M
    Endocr J; 2015; 62(1):13-20. PubMed ID: 25252844
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incretin therapies: highlighting common features and differences in the modes of action of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors.
    Nauck M
    Diabetes Obes Metab; 2016 Mar; 18(3):203-16. PubMed ID: 26489970
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Presentations at the 81st scientific sessions of the American Diabetes Association, part 2.
    Bloomgarden ZT
    J Diabetes; 2021 Nov; 13(11):844-846. PubMed ID: 34396702
    [No Abstract]   [Full Text] [Related]  

  • 20. Newer classes of antidiabetes drugs: ophthalmological considerations for GLP-1R agonists, DPP-4 inhibitors, and SGLT-2 inhibitors.
    McReelis KD; Lovshin JA
    Can J Ophthalmol; 2017 Nov; 52 Suppl 1():S4-S7. PubMed ID: 29074013
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.